Clene Inc.

NASDAQ:CLNN

Biotechnology

Healthcare
$3.66 +1.35%

+$0.08 today

Market cap
$52.70M
Beta
0.92
P/E (TTM)
-2.1
EPS (TTM)
-$2.88
52W Low $3.25High $13.50

Volume 0.12M

Average 0.50M

CLNN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Clene Inc.NASDAQ: CLNN

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $329K fell 77.8% year over year, behind the -17.9% change in trailing-twelve-month research & development. Sequentially, it fell 94.0% from the prior quarter. Over 3 fiscal years it compounded at -24.0% a year.

Context

  • Research & development amounted to 7005.5% of revenue in FY2025, up 1140.6 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -77.8% toward the trailing-twelve-month pace of -17.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$329K-94.0% QoQ
Last fiscal yearDec 2025
$14.01M-30.1% YoY
LTMMar 2026
$12.86M-17.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-77.8%——
1 year-30.1%——
3-year CAGR-24.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
14.01M USD
Year-over-year change
-30.1%
4-year CAGR
-16.2%

Research & Development vs competitors

How CLNN compares with its peers on the latest reported figures

  • CLNN's LTM Mar 2026 research & development of $12.86M is the 10th highest of the 11 companies compared; the peer median is $58.42M.
  • Its year-over-year change of -17.9% is the 6th highest of 11, against a peer median of -14.4%.
  • Research & development amounts to 9596.3% of revenue for CLNN, versus a peer median of 3629.9%.
CLNN Competitors Peer median
Research & Development for CLNN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COYACoya Therapeutics, Inc.LTM Mar 2026$3.68B +26273.1%+50.2%46313.4%
MGNXMacroGenics, Inc.LTM Mar 2026$135.36M -19.9%-12.2%86.2%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$108.76M -25.2%-14.7%—
WHWKWhitehawk Therapeutics IncLTM Mar 2026$99.41M +115.1%+40.7%—
PLRXPliant Therapeutics, Inc.LTM Mar 2026$79.04M -54.8%+4.0%—
CNTBConnect Biopharma Holdings LimitedFY2025$37.8M +29.2%-26.9%59059.4%
STTKShattuck Labs, Inc.LTM Mar 2026$36.3M -40.4%-24.8%3629.9%
CNTXContext Therapeutics Inc.LTM Mar 2026$35.41M +46.4%+65.0%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$30.07M -8.9%+1.3%422.2%
CLNNClene Inc.LTM Mar 2026$12.86M -17.9%-24.0%9596.3%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$5.77M -21.5%-38.7%—
Peer median (excluding CLNN) $58.42M-14.4%-5.5%3629.9%

Competitors are the stored peer set for CLNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue723K473K654K342K200K
Cost of Revenue289K26K121K70K43K
Gross Profit434K447K533K272K157K
Gross Margin60.0%94.5%81.5%79.5%78.5%
Research & Development28.42M31.92M26.66M20.06M14.01M
Selling, General & Admin18.81M16.16M14.42M13.31M9.23M
Operating Expenses50.41M48.86M41.07M33.37M23.24M
Depreciation & Amortization955K1.02M1.71M1.65M1.5M
EBITDA(8.34M)(25.6M)(43.24M)(33.69M)(22M)
EBITDA Margin-1153.9%-5412.9%-6611.8%-9851.2%-10998.0%
Operating Income(49.98M)(48.41M)(40.54M)(33.09M)(23.08M)
Operating Margin-6912.6%-10234.5%-6198.8%-9676.3%-11541.5%
Interest Income001.39M865K223K
Interest Expense870K3.3M4.56M4.06M2.68M
Other Income / Expenses39.81M18.49M(8.96M)(6.31M)(3.09M)
Income Before Tax(10.17M)(29.92M)(49.5M)(39.4M)(26.17M)
Pre-Tax Margin-1406.4%-6325.2%-7569.4%-11520.5%-13086.5%
Income Tax Expense(428K)0000
Net Income(9.74M)(29.92M)(49.5M)(39.4M)(26.17M)
Net Margin-1347.2%-6325.2%-7569.4%-11520.5%-13086.5%
EPS (Basic)(3.16)(4.69)(9.43)(5.67)(2.65)
EPS (Diluted)(3.16)(4.69)(9.43)(5.67)(2.65)
Weighted Avg Shares3.08M3.26M5.25M6.95M9.86M
Weighted Avg Shares (Diluted)3.08M3.26M5.25M6.95M9.86M

Clene Inc.

NASDAQ:CLNN

Intrinsic Alpha fair value

Locked

Current Price

$3.66

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.